Platinum-based Chemotherapy In The Treatment Of Triple-negative Breast Cancer: Asystematic Review

Objective: To assess the clinical efficacy and safety of platinum-based chemotherapy in the treatment of triple-negative breast cancer(TNBC).Methods: Several databases,such as The PubMed,EM base,CBM,CNKI VIP and Cochrane Library.for clinical trials on platinum-based chemotherapy and non-platinum-based chemotherapy for TNBC,were electronically searched.Two reviewers independently screened literature according to the inclusion and exclusion criteria,extracted data,and assessed methodological quality.Meta-analysis was performed using RevMan5.3.Results: Ten trials involving a total of 1367 patients were included.There were significant differences in objective response rate(ORR),pathological complete response(pCR)rate,thrombocytopenia and anemia(P<0.05).There was no significant difference in terms of median overall survival(OS),median progression-free survival(PFS),nausea and vomiting and leucopenia(P>0.05).Conclusion: Platinum-based chemotherapy can improve ORR and pCR in patients with TNBC,but it may increase the incidence of thrombopenia and anemia.Clinical selection process needs to balance its pros and cons.